enVVeno Medical Corporation·Healthcare
enVVeno Medical Corporation, a clinical-stage medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease. The company's lead product is the VenoValve, a replacement venous valve for the treatment of venous chronic venous insufficiency. Its VenoValve implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The company also develops enVVe, a non-surgical and transcatheter-based replacement venous valve system consisting of the enVVe valve, enVVe delivery system, and delivery system accessories. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.
Healthcare
Medical - Devices
37
2018-05-31
1.08

First-Ever FDA IDE Approval for a U.S. Pivotal Study of a Non-surgical Replacement Venous Valve IDE approval positions enVVeno to advance what could become the first effective treatment option for the approximately 3 million U.S. patients suffering from DVI Watch the "What This Means" video here IRVINE, CA / ACCESS Newswire / May 12, 2026 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno Medical" or the "Company"), today announced that Robert Berman, Chief Executive Officer of enVVeno Medical participated in a Virtual Investor "What This Means" segment. As part of the segment, Mr.

Company ended the first quarter with approximately $25 million in cash and investments Capital on hand should fund operations through multiple key milestones into Q3 2027 Company recently received FDA IDE approval to commence TAVVE U.S. Pivotal Study for non-surgical replacement venous valve, enVVe System TAVVE site selection is underway with patient enrollment expected to commence later this year IRVINE, CA / ACCESS Newswire / May 7, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today reported financial results for the first quarter 2026, ending the quarter with approximately $25 million in cash and investments and confirming the Company's strategic focus on the development of its next-generation enVVe® System for the treatment of deep venous insufficiency. "With a strong balance sheet, significant physician interest in the enVVe valve, and a clearly defined regulatory pathway, we are well positioned to execute the TAVVE study and advance the Company towards multiple near-term and long-term milestones," said Robert Berman, Chief Executive Officer of enVVeno Medical.

First-in-Class enVVe system to be evaluated in TAVVE U.S. Pivotal Trial Clinical site activation and patient enrollment expected to commence later this year Large unmet clinical need for approximately 3 million U.S. patients with severe deep Chronic Venous Insufficiency Potential multi-billion-dollar untapped U.S. market Company has approximately $25 million in cash and investments to fund operations into Q3 2027 IRVINE, CA / ACCESS Newswire / April 29, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that the U.S. Food and Drug Administration (FDA) has awarded the Company the first-ever IDE approval to proceed with a U.S. pivotal study of a non-surgical replacement venous valve. The Transcatheter Venous Valve Endoprosthesis (TAVVE®) pivotal study will evaluate the Company's minimally invasive enVVe® System for patients with severe deep Chronic Venous Insufficiency (CVI).

Company accelerated development of the enVVe® System, completing pre-clinical studies and progressing toward a 2026 pivotal trial initiation Strong financial position expected to provide an operating runway into mid-2027 through the achievement of key clinical milestones IRVINE, CA / ACCESS Newswire / March 27, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today announced financial results for the year ended December 31, 2025 and provided a corporate update highlighting its strategic focus on the development of its next-generation enVVe® System. Robert Berman, Chief Executive Officer of enVVeno Medical Corporation, stated, "2025 represented a significant inflection point for the Company.

NEWPORT BEACH, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- NorthStrive Fund II LP (“NorthStrive Fund II”), a subsidiary of NorthStrive Companies Inc., headquartered in Newport Beach, California, and beneficial owner of approximately 5.05% of the outstanding common stock of enVVeno Medical Corporation (“enVVeno” or the “Company”), today issued the following open letter to the Company's Board of Directors (the “Board”) and fellow shareholders:

Pressure BioSciences (OTCMKTS:PBIO - Get Free Report) and enVVeno Medical (NASDAQ: NVNO - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership and risk. Analyst Ratings This is a summary of